Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jul 24;83(4):544–549. doi: 10.1054/bjoc.2000.1294

Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel

R Veitia 1,2, S David 3, P Barbier 3, M Vantard 4, P Gounon 5, M C Bissery 6, A Fellous 3
PMCID: PMC2374667  PMID: 10945505

Abstract

We have studied the state of microtubule associated protein 2 (MAP2) in the pancreatic ductal adenocarcinomas P03 and P02 (sensitive and refractory to docetaxel respectively) since they express the corresponding mRNA and MAP2-related peptides. Immunohistochemical localization showed that in tumour P03 the MAP2-related peptides are highly expressed and confined to the epithelial malignant cells while in P02 the intensity of the immunostaining is lower. However, anti α-tubulin staining followed a similar pattern suggesting that the net amount of macromolecular structures in the sensitive tumour is higher than in the refractory one. This may explain its higher sensitivity to docetaxel, because tubulin assembled into microtubules is the target of the drug. We found that protein extracts from both tumours differed in their proteolytic activity on rat brain MAP2. Since the proteolysis pattern obtained was similar to the one produced by Cathepsin D, we studied the effect of MAP2 proteolysed by this enzyme on microtubule formation in vitro. Proteolysis was found to increase the tendency of tubulin to assemble into macromolecular structures (microtubules and aggregates) in the presence of docetaxel. This suggests that in vivo proteolysis of MAP2 might increase microtubule alterations and potentiate the antitumour effect of docetaxel. © 2000 Cancer Research Campaign

Full Text

The Full Text of this article is available as a PDF (327.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bissery M. C., Guénard D., Guéritte-Voegelein F., Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991 Sep 15;51(18):4845–4852. [PubMed] [Google Scholar]
  2. Bissery M. C., Nohynek G., Sanderink G. J., Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs. 1995 Jun;6(3):339-55, 363-8. doi: 10.1097/00001813-199506000-00001. [DOI] [PubMed] [Google Scholar]
  3. Combeau C., Commerçon A., Mioskowski C., Rousseau B., Aubert F., Goeldner M. Predominant labeling of beta- over alpha-tubulin from porcine brain by a photoactivatable taxoid derivative. Biochemistry. 1994 May 31;33(21):6676–6683. doi: 10.1021/bi00187a038. [DOI] [PubMed] [Google Scholar]
  4. Fellous A., Francon J., Lennon A. M., Nunez J. Microtubule assembly in vitro. Purification of assembly-promoting factors. Eur J Biochem. 1977 Aug 15;78(1):167–174. doi: 10.1111/j.1432-1033.1977.tb11726.x. [DOI] [PubMed] [Google Scholar]
  5. Fellous A., Prasad V., Ohayon R., Jordan M. A., Ludueña R. F. Removal of the projection domain of microtubule-associated protein 2 alters its interaction with tubulin. J Protein Chem. 1994 May;13(4):381–391. doi: 10.1007/BF01901694. [DOI] [PubMed] [Google Scholar]
  6. Fromes Y., Gounon P., Veitia R., Bissery M. C., Fellous A. Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel. J Protein Chem. 1996 May;15(4):377–388. doi: 10.1007/BF01886864. [DOI] [PubMed] [Google Scholar]
  7. Haber M., Burkhart C. A., Regl D. L., Madafiglio J., Norris M. D., Horwitz S. B. Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem. 1995 Dec 29;270(52):31269–31275. doi: 10.1074/jbc.270.52.31269. [DOI] [PubMed] [Google Scholar]
  8. Jaffrézou J. P., Dumontet C., Derry W. B., Durán G., Chen G., Tsuchiya E., Wilson L., Jordan M. A., Sikic B. I. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res. 1995;7(10-11):517–527. [PubMed] [Google Scholar]
  9. Lavelle F., Bissery M. C., Combeau C., Riou J. F., Vrignaud P., André S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol. 1995 Apr;22(2 Suppl 4):3–16. [PubMed] [Google Scholar]
  10. Parness J., Horwitz S. B. Taxol binds to polymerized tubulin in vitro. J Cell Biol. 1981 Nov;91(2 Pt 1):479–487. doi: 10.1083/jcb.91.2.479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Plescia O. J., Smith A. H., Grinwich K. Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci U S A. 1975 May;72(5):1848–1851. doi: 10.1073/pnas.72.5.1848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Veitia R., Bissery M. C., Martinez C., Fellous A. Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice. Br J Cancer. 1998 Oct;78(7):871–877. doi: 10.1038/bjc.1998.595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. van Oosterom A. T., Schrijvers D., Schriivers D [corrected to Schrijvers D. ]. Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience. Anticancer Drugs. 1995 Jun;6(3):356–368. doi: 10.1097/00001813-199506000-00002. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES